We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: FDA Approves Roche/Genentech Drug Erivedge to Treat Advanced Skin Cancer Not Treatable with Surgery
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > FDA Approves Roche/Genentech Drug Erivedge to Treat Advanced Skin Cancer Not Treatable with Surgery
BusinessNews

FDA Approves Roche/Genentech Drug Erivedge to Treat Advanced Skin Cancer Not Treatable with Surgery

BarbaraDuck
BarbaraDuck
Share
0 Min Read
SHARE

Basal cell carcinoma is rarely fatal and in many cases surgery is the cure but in some patients is can spread beyond the skin area in to other areas of the body and this is where the new oral drug comes in to help fight and shrink tumors.  image

When the cancer has metastasized, this is about the only option available.  There are a few side effects like loss of hair and food tasting different but the benefits seem to certainly outweigh. The pill is taken once a day and the cost will be around $7k a month.  I do hope insurers start to cover this as it has been an issue in California with covering oral cancer medications.  BD

California Legislature Urging Health Insurance Companies to Cover Chemotherapy–Especially With Breast Cancer Treatments

 

The Food and Drug Administration has for the first time approved a drug to treat advanced cases of the most common skin cancer, basal cell carcinoma, the agency announced Monday.

The drug, a capsule called Erivedge (generically known as vismodegib), treats basal cell carcinoma that has metastasized (spread through the body), or that cannot be treated with surgery.

In a clinical study in 96 people, 30 percent of those with locally advanced basal cell carcinoma (which had spread to surrounding tissue), and 43 percent of those with metastatic cancer (which had spread to distant sites in the body) saw their tumors shrink or heal while taking the drug, according to a statement from the FDA. Patients took one pill by mouth each day. 

Doctors treat non-metastatic cases with surgery, radiation or topical treatments, and have an extremely high success rate. But no other treatments exist for inoperable cases, such as people with tumors that have extended into the brain, or people who would become disfigured from surgery

Basal cell carcinoma is linked to mutations in genes that are part of a signaling pathway called the hedgehog pathway. Erivedge works by inhibiting the hedgehog pathway.

http://vitals.msnbc.msn.com/_news/2012/01/31/10280479-fda-approves-first-drug-for-inoperable-skin-cancer

More Read

Consequences of Telemedicine Legislation
Cue the Confetti! Startups Can Begin Soliciting Investors on Monday
6 Steps to Re-entering the Healthcare Workforce
Are Physicians the Canary in the Coal Mine of Medicine
Health Insurance For Same Sex Couples

 

TAGGED:basal cell carcinomaErivedgeFDAskin cancer
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Health-editorial illustration of the two-way relationship between substance use and disrupted sleep,
How Sleep Disruption Feeds the Addiction Cycle and What You Can Do About It
Addiction Recovery Mental Health Wellness
November 6, 2026
Flat editorial illustration: The article connects routine visual inspection and accurate barrier fit with protection of peristoma
Peristomal Skin Care: Healthy Skin, Irritation Causes, and When to See a WOC Nurse
Health Nursing
November 2, 2026
Flat editorial illustration: Clinical-trial operations editorial illustration combining healthcare and technology: country-specif
Clinical Study Operations Across Eastern European Research Markets
Health
October 31, 2026
Flat editorial illustration: A health-editorial scene of a first pain-management visit, bringing together attentive consultation,
What to Expect at Your First Pain Management Appointment
Therapies Wellness
October 29, 2026

You Might also Like

symptoms and treatments for harm OCD
News

Could You Be Suffering From Harm OCD?

August 15, 2022
How to Prepare_Doctor_app't
Medical EducationNews

How to Prepare for a Second Opinion Doctor Appointment

November 10, 2015

The 5 Biggest Challenges Healthcare Leaders are Facing in 2015

August 5, 2015

Connected Health, Reimbursement, and the Law of Unintended Consequences

September 26, 2012
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?